Delivery Order SPE2DB22D7065-SPE2DB26FH0NA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,708.86 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops in 5ml units. This firm fixed price delivery order, awarded on August 8, 2025, is set to be completed by August 11, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract represents a non-set-aside competitive award, demonstrating AmerisourceBergen's capability to fulfill...
- The Defense Logistics Agency awarded a $1,190.29 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5ml units. This is a non-set-aside competitive award with an ultimate completion date of August 27, 2025, and performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract under AmerisourceBergen's substantial Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5ML units, with a ceiling value of $1,048.25. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The contract is scheduled for ultimate completion on October 16, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,828.70 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops in 5mL quantities. This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of October 31, 2025, issued just one day prior on October 30, 2025. The contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5ML units, with a ceiling value of $1,310.70. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion by September 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,380.55 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops (5 mL units). This firm fixed price, competitively awarded contract was executed on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract represents a non-set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $8,119.48 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops (5 mL units) on September 24, 2025, with completion scheduled for September 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,757.44 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops (5 mL) under a firm fixed-price contract. The award, issued on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a non-competitive delivery order with no set-aside designation. Performance of this order will be executed from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Olopatadine HCL 0.1% eye drops (5ml) with a ceiling value of $3,491.87. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is due for completion by September 26, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award represents a routine...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5mL quantities, valued at $2,587.17. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. This delivery order is issued...
- SPE2DB22D7065Indefinite Delivery Contract
- SPE2DB22D7065-SPE2DB26FH0NADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops (5ml) with a ceiling value of $1,584.58. The award was made on October 30, 2025, with an ultimate completion date of October 31, 2025, under a firm fixed-price contract type with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's portfolio encompasses a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains, including specialty medications, vaccines, and medical devices. All of the company's reviewed contract awards with DLA have been competitively awarded without set-aside designations, demonstrating its capability to meet federal procurement requirements through open competition. This delivery order represents a routine pharmaceutical supply need within the broader context of AmerisourceBergen's extensive federal medical supply operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 10/30/25 |